{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-016251","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2022-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.196314+00:00","generated_at":"2026-06-24T01:32:19.894269+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tango Therapeutics Q2 2022 net loss $24.9M; TNG908 Orphan Drug Designation","bullets":["Cash, cash equivalents and marketable securities $416.4M as of June 30, 2022.","Net loss $24.9M ($0.28/share) vs $4.5M ($0.09) in Q2 2021; R&D expense $23.7M vs $19.1M.","TNG908 Phase 1/2 enrolling MTAP-deleted solid tumors; FDA Orphan Drug Designation for MPNST.","TNG462 (45-fold more potent PRMT5 inhibitor) and TNG260 declared development candidates; IND filings expected 1H 2023.","Added to Russell 2000, 3000 and Microcap indexes in June 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-016251","json":"https://secwatch.observer/filing/0000950170-22-016251.json","markdown":"https://secwatch.observer/filing/0000950170-22-016251.md","text":"https://secwatch.observer/filing/0000950170-22-016251.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000095017022016251/0000950170-22-016251-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000095017022016251/tngx-20220810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:32:19.894269+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}